林和志
About 林和志
林和志 is a Medical Specialist at Bristol-Myers Squibb in Taiwan, with a background in pharmacy and pharmacology and a track record of exceeding sales targets and implementing successful programs.
Current Role at Bristol-Myers Squibb
林和志 is currently serving as a Medical Specialist at Bristol-Myers Squibb in Taiwan. His role involves leveraging his expertise in pharmacology and medical products to support key initiatives within the organization. Through his work, he plays a crucial part in promoting medical products and maintaining strong affiliations with healthcare institutions.
Previous Experience at DKSH
In 2013, 林和志 worked as a Product Sales Representative at DKSH for three months. During his brief tenure, he focused on promoting and selling medical products, contributing to the company's commercial objectives in the Taiwan market.
Pharmacist Experience at Taipei Medical University Hospital
林和志 gained significant experience working as a Pharmacist at Taipei Medical University Hospital from 2010 to 2012. During these two years, he was responsible for dispensing medications, advising on prescription drugs, and collaborating with medical staff to ensure optimal patient care.
Educational Background in Pharmacology and Pharmacy
林和志 studied at National Yang Ming University, where he earned a Master's degree in Pharmacology from 2005 to 2007. Prior to that, he completed his Bachelor of Pharmacy (BPharm) at Taipei Medical University between 2001 and 2005. His robust educational background laid a strong foundation for his career in the medical and pharmaceutical fields.
Sales Achievements and Program Implementations
林和志 has demonstrated remarkable success in sales and program implementations throughout his career. In 2020, he achieved 113% of the total sales target for Abraxane® and significantly increased its growth rate at key hospitals. In 2016, he implemented the HCV Dual self-pay program, leading to a 55% market share after health insurance reimbursement in 2017. Additionally, he has successfully listed important drugs like HCV Dual and Baraclude® in major hospitals and consistently exceeded sales targets for Baraclude® over several years, including winning the Top Sales Award in 2015.